[
  {
    "ts": "2025-11-06T05:38:45+00:00",
    "headline": "Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions",
    "summary": "Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market responded negatively due to ongoing concerns about oncology revenue and broader commercial headwinds. Management credited the quarter’s performance to robust demand for Biktarvy and Descovy, as well as the successful launch of Yeztugo for HIV prevention and Livdelzi for liver disease. CEO Daniel O’Day specifically highlighted the company’s “disciplined operating expense manage",
    "url": "https://finance.yahoo.com/news/gilead-sciences-q3-earnings-call-053845749.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "dd6bc9c8-d924-3413-b44c-330529de51f5",
      "content": {
        "id": "dd6bc9c8-d924-3413-b44c-330529de51f5",
        "contentType": "STORY",
        "title": "Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions",
        "description": "",
        "summary": "Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market responded negatively due to ongoing concerns about oncology revenue and broader commercial headwinds. Management credited the quarter’s performance to robust demand for Biktarvy and Descovy, as well as the successful launch of Yeztugo for HIV prevention and Livdelzi for liver disease. CEO Daniel O’Day specifically highlighted the company’s “disciplined operating expense manage",
        "pubDate": "2025-11-06T05:38:45Z",
        "displayTime": "2025-11-06T05:38:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "GILD Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7IhZSScYZ4CvnQJJpve_Dg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cv.0mSrHV7hG2Zeh2xc10A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-q3-earnings-call-053845749.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-q3-earnings-call-053845749.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:00:00+00:00",
    "headline": "Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases",
    "summary": "Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (“Accipiter Bio”), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from stealth with",
    "url": "https://finance.yahoo.com/news/accipiter-biosciences-emerges-stealth-12-120000362.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "792a147e-6e7a-3d78-b07e-d02a2f3dc5c7",
      "content": {
        "id": "792a147e-6e7a-3d78-b07e-d02a2f3dc5c7",
        "contentType": "STORY",
        "title": "Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases",
        "description": "",
        "summary": "Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (“Accipiter Bio”), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from stealth with",
        "pubDate": "2025-11-06T12:00:00Z",
        "displayTime": "2025-11-06T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/30bed581fbd1bf65f619bc3449ca564c",
          "originalWidth": 2404,
          "originalHeight": 669,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TczC315ovJ4ZaOckt0ONjA--~B/aD02Njk7dz0yNDA0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/30bed581fbd1bf65f619bc3449ca564c.cf.webp",
              "width": 2404,
              "height": 669,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nwHooGBhqjyBZ5rEFHWJnA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/30bed581fbd1bf65f619bc3449ca564c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/accipiter-biosciences-emerges-stealth-12-120000362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/accipiter-biosciences-emerges-stealth-12-120000362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "4502.T"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]